Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Does Trop2 expression matter in the context of Dato-DXd treatment of mBC?
Data from the FDA review shows no association between Trop2 expression and outcomes with Dato-DXd in TB01.
The mechanism of action of modern ADCs remains far from being elucidated.”
More posts featuring Paolo Tarantino.